Navigation Links
Evidence against use of Beta blockers as first choice in the treatment of primary hypertension

Beta blockers have been used widely in the treatment of hypertension and are still recommended as first-line drugs in hypertension guidelines. Moreover, after myocardial infarction and in patients with heart failure, treatment // with beta blockers prevents re-infarction, hospitalisation for heart failure, and premature death. However, a preliminary analysis has shown that atenolol is not very effective in hypertension.

A recent study, published in the October-November issue of The Lancet, was conducted with the aim to substantially enlarge previous data on atenolol and analyse the effect of different beta blockers on stroke, myocardial infarction, and mortality of all causes .

For the study, the Cochrane Library and PubMed were searched for beta blocker treatment in patients with primary hypertension. Data were then entered into the Cochrane Collaboration Review Manager package and were summarised in meta-analyses. 13 randomised controlled trials were included in a meta-analysis comparing treatment with beta blockers with other antihypertensive drugs. Seven studies were included in a comparison of beta blockers and placebo or no treatment..

Results obtained showed that the relative risk of stroke was 16% higher for beta blockers than for other drugs. There was no difference for myocardial infarction. When the effect of beta blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19% for all beta blockers, about half that expected from previous hypertension trials. There was no difference for myocardial infarction or mortality.

The authors conclude that in comparison with other antihypertensive drugs, the effect of beta blockers is less than optimum, with a raised risk of stroke.

The authors suggest that beta blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled tr ials of hypertension.


Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Evidence supporting H.pylori eradication
3. Evidences that Better Health Care Facility is Offered By Public Hospitals.
4. First Conclusive Evidence Linking Oral Bacteria To Premature Babies
5. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
6. No Clear Evidence for Ultra-Low Cholesterol Targets?
7. Lack of Evidence on Treatment for Narrowed Kidney Arteries
8. Some Evidence Shows Chinese Herbal Medicine Helps Angina Patients
9. Strong Evidence Suggests Incidence Of Mating Of Ancestors With Neanderthals
10. Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition
11. Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine?
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: